According to the suit, those manufacturers have aggressively increased their prices for Insulin far beyond the prices they would have charged if there were no kickback scheme. (Photo: Shutterstock)
A group of drug manufacturers and pharmacy benefit managers are accused in a class action suit of artificially inflating prices for analog insulin.
The suit claims drug manufacturers Eli Lilly and Co., Novo Nordisk and Sanofi Aventis U.S. maintain or increase their sales by paying bribes and kickbacks to pharmacy benefit managers CVS, Express Scripts, Medco Health Solutions, United Health and OptumRX in the form of rebates, fees, discounts or other payments or financial incentives in exchange for inclusion or favorable placement of the manufacturers' respective Insulin products on the defendant's formularies.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Charles Toutant
Charles Toutant is a litigation writer for the New Jersey Law Journal.
